128 related articles for article (PubMed ID: 28396899)
21. The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma.
Lehnerdt GF; Franz P; Bankfalvi A; Grehl S; Kelava A; Nückel H; Lang S; Schmid KW; Siffert W; Bachmann HS
Ann Oncol; 2009 Jun; 20(6):1094-9. PubMed ID: 19196738
[TBL] [Abstract][Full Text] [Related]
22. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
[TBL] [Abstract][Full Text] [Related]
23. Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder.
Hess J; Stelmach P; Eisenhardt A; Rübben H; Reis H; Schmid KW; Bachmann HS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1659-1670. PubMed ID: 28417194
[TBL] [Abstract][Full Text] [Related]
24. Association of rs6983561 polymorphism at 8q24 with prostate cancer mortality in a Japanese population.
Suzuki M; Liu M; Kurosaki T; Suzuki M; Arai T; Sawabe M; Kasuya Y; Kato M; Fujimura T; Fukuhara H; Enomoto Y; Nishimatsu H; Ishikawa A; Kume H; Homma Y; Kitamura T
Clin Genitourin Cancer; 2011 Sep; 9(1):46-52. PubMed ID: 21700508
[TBL] [Abstract][Full Text] [Related]
25. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
26. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
27. Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy.
Foster CC; Jackson WC; Foster BC; Johnson SB; Feng FY; Hamstra DA
Radiat Oncol; 2014 Nov; 9():245. PubMed ID: 25424123
[TBL] [Abstract][Full Text] [Related]
28. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.
Amini A; Rusthoven CG; Jones BL; Armstrong H; Raben D; Kavanagh BD
Urol Oncol; 2016 Apr; 34(4):165.e1-9. PubMed ID: 26699831
[TBL] [Abstract][Full Text] [Related]
29. Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy.
Wang Y; Yin W; Wang Z; Huang J; Pan J; Zhu Y; Xu F; Shao X; Sha J; Cai Y; Liu Q; Dong B; Xue W; Huang Y
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):209-15. PubMed ID: 26951714
[TBL] [Abstract][Full Text] [Related]
30. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.
Feng FY; Blas K; Olson K; Stenmark M; Sandler H; Hamstra DA
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):64-71. PubMed ID: 23462420
[TBL] [Abstract][Full Text] [Related]
31. Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy.
Tendulkar RD; Reddy CA; Stephans KL; Ciezki JP; Klein EA; Mahadevan A; Kupelian PA
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1397-404. PubMed ID: 21665379
[TBL] [Abstract][Full Text] [Related]
32. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
33. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
[TBL] [Abstract][Full Text] [Related]
35. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
36. Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence.
Gu C; Li Q; Zhu Y; Qu Y; Zhang G; Wang M; Yang Y; Wang J; Jin L; Wei Q; Ye D
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):310-6. PubMed ID: 26238235
[TBL] [Abstract][Full Text] [Related]
37. Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancer.
Heubner M; Wimberger P; Otterbach F; Kasimir-Bauer S; Siffert W; Kimmig R; Nückel H
Int J Biol Markers; 2009; 24(4):223-9. PubMed ID: 20082279
[TBL] [Abstract][Full Text] [Related]
38. Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.
Lilleby W; Narrang A; Tafjord G; Vlatkovic L; Russnes KM; Stensvold A; Hole KH; Tran P; Eilertsen K
Radiat Oncol; 2015 Nov; 10():232. PubMed ID: 26577452
[TBL] [Abstract][Full Text] [Related]
39. ATM, BCL2, and TGFβ Gene Polymorphisms as Radiotherapy Outcome Biomarkers in Head and Neck Squamous Cell Carcinoma Patients.
Agostini LP; Stur E; Garcia FM; Ventorim DP; Dos Reis RS; Dettogni RS; Dos Santos EVW; Peterle GT; Maia LL; Mendes SO; de Carvalho MB; Tajara EH; de Paula F; Dos Santos M; da Silva AMA; Louro ID
Genet Test Mol Biomarkers; 2017 Dec; 21(12):727-735. PubMed ID: 29135311
[TBL] [Abstract][Full Text] [Related]
40. Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation.
Fujimoto N; Kubo T; Inatomi H; Bui HT; Shiota M; Sho T; Matsumoto T
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):336-40. PubMed ID: 23896625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
